10.6084/m9.figshare.7151810.v1
Ilya Valerevich Smirnov
Ilya Valerevich
Smirnov
Irina Vladimirovna Gryazeva
Irina Vladimirovna
Gryazeva
Margarita Yurevna Vasileva
Margarita Yurevna
Vasileva
Irina Yurevna Krutetskaia
Irina Yurevna
Krutetskaia
Olga Alexandrovna Shashkova
Olga Alexandrovna
Shashkova
Marina Platonovna Samoylovich
Marina Platonovna
Samoylovich
Anastasia Yurevna Stolbovaya
Anastasia Yurevna
Stolbovaya
Nellya Grigorevna Solodovnikova
Nellya Grigorevna
Solodovnikova
Irina Evegnevna Zazerskaya
Irina Evegnevna
Zazerskaya
Dmitriy Igorevich Sokolov
Dmitriy Igorevich
Sokolov
Sergey Alexeevich Selkov
Sergey Alexeevich
Selkov
Vladimir Borisovich Klimovich
Vladimir Borisovich
Klimovich
New highly sensitive sandwich ELISA system for soluble endoglin quantification in different biological fluids
Taylor & Francis Group
2018
Soluble endoglin
ELISA
monoclonal antibody
preeclampsia
protein heterogeneity
2018-10-01 09:45:27
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/New_highly_sensitive_sandwich_ELISA_system_for_soluble_endoglin_quantification_in_different_biological_fluids/7151810
<p>Soluble endoglin (sEng) is a fragment of a membrane-associated receptor (CD105) expressed on endothelial cells, mesenchymal stem cells and trophoblast cells. It is considered as a regulatory factor involved in the development of preeclampsia (PE) and cancer-associated neo-angiogenesis. The purpose of this study was to describe a new sandwich ELISA for sEng quantification. In contrast to three commercial kits, the new ELISA was able to quantify sEng not only in blood plasma and cell culture supernatants, but also in urine and cerebrospinal fluid. The assay detected up to two orders of magnitude higher antigen levels than did the commercial kits. Using Western blot assay followed by SDS-PAGE or Blue Native PAGE, we demonstrated a heterogeneous nature of sEng molecules. Antigen heterogeneity is considered as a factor contributing to the pronounced differences in its content estimations by different ELISAs. We obtained evidence indicating that the assay was capable of detecting heterogenious sEng molecules. The new ELISA was validated as a quick, specific and accurate method for sEng quantification. Despite the differences in antigen content estimates, the assay had similar diagnostic performance as widely used commercial kit for the detection of severe PE in pregnant women based on plasma sEng contents. Moreover, the new assay was able to delineate diseased patients based on antigen levels in urine. Therefore, the new ELISA is a potentially valuable tool for <i>in vitro</i> and clinical studies.</p>